BridgeBio has demonstrably boosted its progress of the novel treatment for ATTR-CM, leveraging the investigational drug. Preliminary patient information suggests promising benefits for patients diagnosed with a severe https://biotech131742.is-blog.com/49104150/company-improves-attr-cm-management-using-the-therapy